Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)

被引：0
|
作者：
Falcone, A.
Brunetti, I. M.
Benedetti, G.
Evangelista, W.
Picone, V.
Vitello, S.
Rosso, R.
Granetto, C.
Porcile, G.
Masi, G.
机构：
[1] Univ Study Pisa, Osped Civile, UO Oncol Med, Livorno, Italy
[2] Osped S Chiara, UO Oncol Med, Pisa, Italy
[3] Osped Bellaria, UO Oncol Med, Bologna, Italy
[4] Osped S Giovanni Molinette, COES, Turin, Italy
[5] Policlin Umberto 1, UO Oncol Med, Rome, Italy
[6] Osped S Elia, UO Oncol Med, Caltanissetta, Italy
[7] IST, Genoa, Italy
[8] Osped S Croce & Carle, SC Oncol Med, Cuneo, Italy
[9] Osped S Lazzaro, UO Oncol, Alba, Italy
[10] Osped Civile, UO Oncol Med, Livorno, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [31] FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
    Fornaro, L.
    Lonardi, S.
    Masi, G.
    Loupakis, F.
    Bergamo, F.
    Salvatore, L.
    Cremolini, C.
    Schirripa, M.
    Vivaldi, C.
    Aprile, G.
    Zaniboni, A.
    Bracarda, S.
    Fontanini, G.
    Sensi, E.
    Lupi, C.
    Morvillo, M.
    Zagonel, V.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2062 - 2067
  • [32] Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
    Modest, Dominik Paul
    Heinemann, Volker
    Schuett, Philipp
    Angermeier, Stefan
    Haberkorn, Mike
    Waidmann, Oliver
    Graeven, Ullrich
    Wille, Kai
    Kunzmann, Volker
    Henze, Larissa
    Constantin, Christian
    de Wit, Maike
    Denzlinger, Claudio
    Ballhausen, Alexej
    Kurreck, Annika
    Jelas, Ivan
    Alig, Annabel Helga Sophie
    Stahler, Arndt
    Stintzing, Sebastian
    Oettle, Helmut
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
  • [33] Folfoxiri compared to folfiri as first-line treatment of metastic colorectal cancer (MCRC): Updated results, multivariate and subgroups analisys of the GONO randomized phase III study
    Falcone, A.
    Andreuccetti, M.
    Ricci, S.
    Orlandini, C.
    Barbara, C.
    Evangelista, W.
    Ciuffreda, L.
    Cortesi, E.
    Ferraldeschi, R.
    Chiara, S.
    Granetto, C.
    Loupakis, F.
    Bursi, S.
    Allegrini, G.
    Masi, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII28 - VII28
  • [34] Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer: after 5-FU failure
    Schmitt, C
    Blijham, G
    Jolain, B
    Rougier, P
    Van Cutsem, E
    ANTI-CANCER DRUGS, 1999, 10 (06) : 617 - 623
  • [35] Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC)
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezael
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III "BEBYP" trial by the Gruppo Oncologico Nord Ovest (GONO)
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Cremolini, Chiara
    Fornaro, Lorenzo
    Schirripa, Marta
    Granetto, Cristina
    Miraglio, Emanuela
    Di Costanzo, Francesco
    Antonuzzo, Lorenzo
    Marcucci, Lorenzo
    Barbara, Cecilia
    Boni, Corrado
    Banzi, Maria
    Chiara, Silvana
    Garbarino, Daniela
    Valsuani, Chiara
    Bonetti, Andrea
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status - a Phase II Study by the GONO Group
    Fornaro, L.
    Loupakis, F.
    Lonardi, S.
    Masi, G.
    Salvatore, L.
    Cremolini, C.
    Bergamo, F.
    Cappetta, A.
    Zagonel, V.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S420 - S420
  • [38] Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir)+5FU/LV (IrFL) followed by docetaxel (T)+5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
    Loupakis, F.
    Masi, G.
    Bursi, S.
    Picone, V.
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Murr, R.
    Antonuzzo, A.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancer
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezaei
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21
  • [40] Capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 239
12345